BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 15755004)

  • 1. The relationship between mutant p53 gene, DNA contents and conventional clinicopathological prognostic variables in cases with endometrial carcinoma.
    Osmanağaoğlu MA; Kadioğlu S; Osmanağaoğlu S; Bozkaya H; Reis A; Tekelioğlu Y
    Eur J Gynaecol Oncol; 2005; 26(1):64-70. PubMed ID: 15755004
    [TBL] [Abstract][Full Text] [Related]  

  • 2. p53 overexpression as a prognostic indicator in endometrial carcinoma.
    Ozalp S; Yalcin OT; Tanir HM; Kabukcuoglu S; Erol G
    Eur J Gynaecol Oncol; 2003; 24(3-4):275-8. PubMed ID: 12807239
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multivariable analysis of DNA ploidy, p53, and HER-2/neu as prognostic factors in endometrial cancer.
    Lukes AS; Kohler MF; Pieper CF; Kerns BJ; Bentley R; Rodriguez GC; Soper JT; Clarke-Pearson DL; Bast RC; Berchuck A
    Cancer; 1994 May; 73(9):2380-5. PubMed ID: 7909491
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Leiomyosarcoma of the uterus: A clinicopathologic, DNA flow cytometric, p53, and mdm-2 analysis of 49 cases.
    Blom R; Guerrieri C; Stâl O; Malmström H; Simonsen E
    Gynecol Oncol; 1998 Jan; 68(1):54-61. PubMed ID: 9454661
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic factors in surgical stage I endometrial carcinoma.
    Lundgren C; Auer G; Frankendal B; Nilsson B; Nordström B
    Acta Oncol; 2004; 43(1):49-56. PubMed ID: 15068320
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic significance of L1CAM expression and its association with mutant p53 expression in high-risk endometrial cancer.
    Van Gool IC; Stelloo E; Nout RA; Nijman HW; Edmondson RJ; Church DN; MacKay HJ; Leary A; Powell ME; Mileshkin L; Creutzberg CL; Smit VT; Bosse T
    Mod Pathol; 2016 Feb; 29(2):174-81. PubMed ID: 26743472
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic significance of DNA topoisomerase II-alpha (Ki-S1) immunoexpression in endometrial carcinoma.
    Bildrici K; Tel N; Ozalp SS; Yalcin OT; Yilmaz V
    Eur J Gynaecol Oncol; 2002; 23(6):540-4. PubMed ID: 12556100
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular and cytokinetic pretreatment risk assessment in endometrial carcinoma.
    Silverman MB; Roche PC; Kho RM; Keeney GL; Li H; Podratz KC
    Gynecol Oncol; 2000 Apr; 77(1):1-7. PubMed ID: 10739683
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk factors for lymph node metastases in women with endometrial cancer: A population-based, nation-wide register study-On behalf of the Swedish Gynecological Cancer Group.
    Stålberg K; Kjølhede P; Bjurberg M; Borgfeldt C; Dahm-Kähler P; Falconer H; Holmberg E; Staf C; Tholander B; Åvall-Lundqvist E; Rosenberg P; Högberg T
    Int J Cancer; 2017 Jun; 140(12):2693-2700. PubMed ID: 28340503
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of DNA ploidy analysis in endometrial adenocarcinoma.
    Jhala DN; Atkinson BF; Balsara GR; Hernandez E; Jhala NC
    Ann Diagn Pathol; 2001 Oct; 5(5):267-73. PubMed ID: 11598854
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of DNA ploidy and S-phase fraction in stage I endometrial carcinoma.
    Pfisterer J; Kommoss F; Sauerbrei W; Rendl I; Kiechle M; Kleine W; Pfleiderer A
    Gynecol Oncol; 1995 Aug; 58(2):149-56. PubMed ID: 7622098
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overexpression of p53 protein and DNA content are important biologic prognostic factors for thyroid cancer.
    Nishida T; Nakao K; Hamaji M; Nakahara MA; Tsujimoto M
    Surgery; 1996 May; 119(5):568-75. PubMed ID: 8619214
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Associations between lymphovascular space invasion, nodal recurrence, and survival in patients with surgical stage I endometrioid endometrial adenocarcinoma.
    Veade AE; Foote J; Ehrisman J; Broadwater G; Davidson BA; Lee PS; Secord AA; Berchuck A; Havrilesky LJ
    World J Surg Oncol; 2019 May; 17(1):80. PubMed ID: 31077193
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lymphovascular space invasion as a predictive factor for lymph node metastases and survival in endometrioid endometrial cancer - a Swedish Gynecologic Cancer Group (SweGCG) study.
    Stålberg K; Bjurberg M; Borgfeldt C; Carlson J; Dahm-Kähler P; Flöter-Rådestad A; Hellman K; Hjerpe E; Holmberg E; Kjølhede P; Marcickiewicz J; Rosenberg P; Tholander B; Åvall-Lundqvist E; Högberg T
    Acta Oncol; 2019 Nov; 58(11):1628-1633. PubMed ID: 31373248
    [No Abstract]   [Full Text] [Related]  

  • 15. The outcome of stage I-II clinically and surgically staged papillary serous and clear cell endometrial cancers when compared with endometrioid carcinoma.
    Cirisano FD; Robboy SJ; Dodge RK; Bentley RC; Krigman HR; Synan IS; Soper JT; Clarke-Pearson DL
    Gynecol Oncol; 2000 Apr; 77(1):55-65. PubMed ID: 10739691
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fluorescence in situ hybridization and immunohistochemical analysis of p53 expression in endometrial cancer: prognostic value and relation to ploidy.
    Graesslin O; Chantot-Bastaraud S; Lorenzato M; Birembaut P; Quéreux C; Daraï E
    Ann Surg Oncol; 2008 Feb; 15(2):484-92. PubMed ID: 18071824
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular and histopathologic predictors of distant failure in endometrial cancer.
    Mariani A; Sebo TJ; Webb MJ; Riehle D; Katzmann JA; Keeney GL; Roche PC; Lesnick TG; Podratz KC
    Cancer Detect Prev; 2003; 27(6):434-41. PubMed ID: 14642551
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cell proliferation, measured as flow cytometric S-phase fraction, is a strong prognostic indicator in FIGO stage I endometrioid endometrial carcinoma: a population-based study.
    Green RW; Engblom S; Baldetorp B; Hartman L; Måsbäck A; Bjurberg M
    Acta Obstet Gynecol Scand; 2015 Oct; 94(10):1064-73. PubMed ID: 26123703
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospective analysis of DNA ploidy, proliferative index and epidermal growth factor receptor as prognostic factors for pretreated uterine cancer.
    Nagai N; Oshita T; Fujii T; Kioka H; Katsube Y; Ohama K
    Oncol Rep; 2000; 7(3):551-9. PubMed ID: 10767367
    [TBL] [Abstract][Full Text] [Related]  

  • 20. L1 Cell Adhesion Molecule as a Predictor of Disease-Specific Survival and Patterns of Relapse in Endometrial Cancer.
    Pasanen A; Tuomi T; Isola J; Staff S; Bützow R; Loukovaara M
    Int J Gynecol Cancer; 2016 Oct; 26(8):1465-71. PubMed ID: 27648714
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.